These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases. Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364 [TBL] [Abstract][Full Text] [Related]
25. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy. Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457 [TBL] [Abstract][Full Text] [Related]
26. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109 [TBL] [Abstract][Full Text] [Related]
27. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936 [TBL] [Abstract][Full Text] [Related]
28. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041 [TBL] [Abstract][Full Text] [Related]
29. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549 [TBL] [Abstract][Full Text] [Related]
30. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis. Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355 [TBL] [Abstract][Full Text] [Related]
32. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825 [TBL] [Abstract][Full Text] [Related]
33. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]
34. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Shoji H; Yamada Y; Taniguchi H; Nagashima K; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y Cancer Sci; 2014 Aug; 105(8):1002-7. PubMed ID: 24863535 [TBL] [Abstract][Full Text] [Related]
36. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases. Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938 [TBL] [Abstract][Full Text] [Related]
37. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
39. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664 [TBL] [Abstract][Full Text] [Related]
40. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]